Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorlatinib Monotherapy in ROS1-Positive NSCLC in China
NCT05297890Phase 2Active, not recruiting
- Sponsor
- CStone Pharmaceuticals
- Start
- May 2022
- Primary completion
- Dec 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of lorlatinib in non-small cell lung cancer (NSCLC), sponsored by CStone Pharmaceuticals. Started May 2022; status: active, not recruiting.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05297890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05297890.